What to look out for at the AACR meeting
This article was originally published in Scrip
Executive Summary
This year's American Association of Cancer Research (AACR) meeting in Philadelphia (18-22 April) looks set to reveal data in several hot areas of research such as immune-oncology, including checkpoint inhibitors and PD-1/PD-L1-acting products.
You may also be interested in...
US Approval For ViiV’s ‘Last Resort’ HIV Drug Rukobia
The US FDA has given the go-ahead for marketing of ViiV healthcare’s novel HIV drug just as the EMA removes the accelerated assessment status from its application there.
Executives On The Move: BioXcel Therapeutics Picks A Development Officer, A Finance Hire At RenovaCare And CANbridge Taps Takeda Talent
Immuno-oncology and neuroscience firm BioXcel Therapeutics picks a chief development officer, and stem-cell therapy company RenovaCare hires a CFO. Plus, CANbridge Life Sciences, developer of specialty health products, adds Takeda Pharma rare disease lead as global head, business development.
Genmab And Seattle Genetics Progress Cervical Cancer ADC
Topline Phase II data for the antibody-drug conjugate tisotumab vedotin put it on a swift path towards approval in cervical cancer.
Need a specific report? 1000+ reports available
Buy Reports